Pulmonary arterial hypertension is a progressive disorder in which endothelial dysfunction
and vascular remodeling obstruct small pulmonary arteries, resulting in increased …

Pulmonary arterial hypertension (PAH) is a syndrome in which pulmonary arterial
obstruction increases pulmonary vascular resistance, which leads to right ventricular (RV) …

Although isoform-selective translocation of protein kinase C (PKC) ε appears to play an
important role in the late phase of ischemic preconditioning (PC), the mechanism (s) …

The administration of mesenchymal stem cells (MSCs) has been proposed for the treatment
of pulmonary hypertension. However, the effect of intratracheally administered MSCs on the …

Diazeniumdiolates, compounds of structure R1R2NN (O)= NOR3, which have also been
called NONOates, have proven useful for treating an increasing diversity of medical …

Background—Pulmonary hypertension (PH) is a multifactorial disease characterized by
increased pulmonary vascular resistance and right ventricular failure; morbidity and mortality …

Diazeniumdiolate ions are convenient and, for a variety of applications, uniquely
advantageous nitric oxide (NO) dosage forms. Ionic diazeniumdiolates generate bioactive …

Nitric oxide (NO) is a diffusible gas with diverse roles in human physiology and disease.
Significant progress in the understanding of its biological effects has taken place in recent …

Monocrotaline (MCT) is a toxic pyrrolizidine alkaloid of plant origin. Administration of small
doses of MCT or its active metabolite, monocrotaline pyrrole (MCTP), to rats causes delayed …

Pulmonary hypertension (PH) is an incurable, chronic disease of small pulmonary vessels.
Progressive remodeling of the pulmonary vasculature results in increased pulmonary …